Tenderwize
Wróć do wyszukiwania

Open House Originale Rabattverträge 2024-08 - Fluticason/Vilanterol

Techniker Krankenkasse·Hamburg, Germany·Deadline Sep 30, 2026 · 36 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-08 - Fluticason/Vilanterol (Wirkstoffkombination)

50/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

50 / 100

Złożoność

20 / 100

Czynniki ryzyka

No estimated value or volume is provided. The financial potential of the contract is unknown, complicating bid/no-bid d...

The contract ends automatically on patent expiry. If the patent expires early, the contract may be shorter than expecte...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Sep 2026
  • Conclusion of discount contracts for the active ingredient combination Fluticason/Vilanterol
  • Contracts with uniform conditions, no individual negotiations
Pokaż pełne podsumowanie

Open House procedure by Techniker Krankenkasse (TK) and other German health insurers to conclude discount contracts (Rabattverträge) for the active ingredient combination Fluticason/Vilanterol. The procedure is non-competitive: any eligible pharmaceutical entrepreneur can join at any time during the contract period (until 30 Sept 2026). No estimated value, no award criteria (all accepted). Eligibility focuses on being a pharmaceutical entrepreneur with proper marketing authorization. The notice clarifies this is not a public procurement subject to EU directives.

Ryzyka

No estimated value or volume is provided. The financial potential of the contract is unknown, complicating bid/no-bid d...

The contract ends automatically on patent expiry. If the patent expires early, the contract may be shorter than expecte...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur as per § 4 Abs. 18 AMG regarding the offered medicines
  • Must have a valid marketing authorization for the product in Germany/EU/EEA
  • No convictions for certain criminal or economic offenses (last 5 years for §123 GWB, last 3 years for §124 GWB)

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria; all eligible participants are accepted.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open House Originale Rabattverträge 2024-08 - Fluticason/Vilanterol

Discount contracts for Fluticason/Vilanterol combination. Contract duration max 24 months from 01 Oct 2024, ending 30 Sept 2026. Joining possible anytime during the period. No exclusivity.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Sep 2024 - Sep 2026

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria; all eligible participants are accepted.

Termin

Deadline Sep 30, 2026

Szczegóły zamówienia

Data publikacji
30 Jul 2024
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
461715-2024

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3